First-Line Treatment in Melanoma—Vemurafenib or Ipilumumab: Which To Choose?
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

First-Line Treatment in Melanoma—Vemurafenib or Ipilumumab: Which To Choose?

› Forums › General Melanoma Community › First-Line Treatment in Melanoma—Vemurafenib or Ipilumumab: Which To Choose?

  • Post
Viewing 1 reply thread
  • Replies
      • June 9, 2011 at 3:39 am
      KellieSue
      Participant

      stupid question:

      I'm on B-raf. Is this vemurafenib?

      Kellie(from Iowa) Stage IV on B-raf

      • June 9, 2011 at 3:39 am
      KellieSue
      Participant

      stupid question:

      I'm on B-raf. Is this vemurafenib?

      Kellie(from Iowa) Stage IV on B-raf

        • June 9, 2011 at 6:48 pm
        EmilyandMike
        Participant

         

         

        YES BRAF = VEMURAFENIB

        Recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual meeting of the American Society of Clinical Oncology (ASCO).

        The BRIM 3 study was conducted to compare vemurafenib with dacarbazine (chemotherapy) in patients with previously untreated BRAF V600 mutation-positive, unresected, locally advanced or metastatic melanoma (skin cancer).

        Upon comparison with chemotherapy, the study results demonstrated that patients on vemurafenib experienced a significant improvement in overall survival, with the risk of death reducing by 63%. The study also met the co-primary endpoint of reducing the risk of disease aggravation by 74% compared with chemotherapy.

        Last month, Roche submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), for the use of vemurafenib to treat patients with BRAF V600 mutation-positive metastatic melanoma. Roche also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA), for similar use of the drug.

        • June 9, 2011 at 6:48 pm
        EmilyandMike
        Participant

         

         

        YES BRAF = VEMURAFENIB

        Recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual meeting of the American Society of Clinical Oncology (ASCO).

        The BRIM 3 study was conducted to compare vemurafenib with dacarbazine (chemotherapy) in patients with previously untreated BRAF V600 mutation-positive, unresected, locally advanced or metastatic melanoma (skin cancer).

        Upon comparison with chemotherapy, the study results demonstrated that patients on vemurafenib experienced a significant improvement in overall survival, with the risk of death reducing by 63%. The study also met the co-primary endpoint of reducing the risk of disease aggravation by 74% compared with chemotherapy.

        Last month, Roche submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), for the use of vemurafenib to treat patients with BRAF V600 mutation-positive metastatic melanoma. Roche also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA), for similar use of the drug.

Viewing 1 reply thread
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.